OVID - Ovid Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

155.5M

Cash

117.7M

Avg Qtr Burn

-11.81M

Short % of Float

0.56%

Insider Ownership

20.86%

Institutional Own.

56.40%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Soticlestat (OV935) Details Dravet syndrome, Rare diseases, Rare genetic disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV329 (GABA-AT inhibitor) Details Epilepsy	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details Genetic disorder, Rare genetic disease, Angelman Syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV101 (gaboxadol) Details Rare genetic disease, Fragile X syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV935 (CH24H Inhibitor) Details Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.